The Longevity

“Poop-Tech” App Cara Secures $2M Seed Round

Berlin-based HiDoc Technologies launched its digestive health app Cara in 2016, and this week announced a successful round of seed funding to develop its “precision medicine solution for digestive health”.

Cara…raised $2 million in seed funding led by Atlantic Labs along with a group of undisclosed angel investors…

The Cara team believes digestive health in particular needs the specification made possible through precision medicine.

In 2016, HiDoc Technologies launched the Cara app with the aim to help people with chronic digestive disorders. Today, more than 20% of the world’s population suffer from the Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), reflux and food intolerances. What most of these people have in common, is that they receive conventional one-size-fits-all treatments which only work in some cases or might be ineffective.

Sometimes they cause unnecessary side effects. This leads to frustration among patients who are already in a crisis. One-size-fits-all solutions fail because everyone responds differently to the treatments, due to differences in the individual gut microbial fingerprint, lifestyle and environmental factors. Hence, precision medicine is needed to make treatment more effective, reduce side effects and non-responder rates. Last but not least, it will also save costs.

The Cara app includes a symptom diary, as well as ways to track medication, activity, and food intake. It can then tailor a probiotic solution based on individual microbiome profile as well as symptom evolution.

[AI-powered] algorithms [can analyze how] symptoms evolve and can adjust the probiotic formula….

“Poop tech is the next big thing. Digestive issues are still a taboo topic but we are now making them visible to the public. Digestive diseases are widespread. There are so many people out there suffering from bloating, diarrhea, constipation or stomach pain on a daily basis,” said Jesaja Brinkmann, medical cofounder at Cara in a statement. “Unfortunately, many health practitioners are not up to date with the state-of-the-art treatment options. Also, conventional treatments don’t work for everyone. None of our competitors combine the patient’s individual microbial, lifestyle, environmental and treatment response data as well as predictive treatment outcome algorithms which are needed to learn and offer individualized and appropriate digestive remedies for microbiome optimization and symptom reduction” added Brinkmann.

Leave a Reply

Your email address will not be published. Required fields are marked *